ID: ALA1270901

Max Phase: Preclinical

Molecular Formula: C28H39N5O3S

Molecular Weight: 525.72

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ncnc(C)c1C(=O)N1C[C@H]2CN(CCC(c3ccccc3)C3CCN(S(C)(=O)=O)CC3)C[C@H]2C1

Standard InChI:  InChI=1S/C28H39N5O3S/c1-20-27(21(2)30-19-29-20)28(34)32-17-24-15-31(16-25(24)18-32)12-11-26(22-7-5-4-6-8-22)23-9-13-33(14-10-23)37(3,35)36/h4-8,19,23-26H,9-18H2,1-3H3/t24-,25+,26?

Standard InChI Key:  MKIVNRWVNSAMHK-IQCGEYIDSA-N

Associated Targets(Human)

C-C motif chemokine 5 54 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsomes 16955 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Caco-2 12174 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 3636 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 525.72Molecular Weight (Monoisotopic): 525.2774AlogP: 2.94#Rotatable Bonds: 7
Polar Surface Area: 86.71Molecular Species: BASEHBA: 6HBD: 0
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 9.86CX LogP: 0.62CX LogD: -1.80
Aromatic Rings: 2Heavy Atoms: 37QED Weighted: 0.55Np Likeness Score: -1.07

References

1. Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM..  (2010)  Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.,  20  (22): [PMID:20855212] [10.1016/j.bmcl.2010.08.118]
2. Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM..  (2010)  Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.,  20  (22): [PMID:20855212] [10.1016/j.bmcl.2010.08.118]
3. Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM..  (2010)  Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.,  20  (22): [PMID:20855212] [10.1016/j.bmcl.2010.08.118]

Source